| Mrs Margie Castaneda, RN MSN FNP BC | |
|
2601 Clark Blvd, Laredo, TX 78043 | |
| (956) 795-4774 | |
| (956) 795-0147 |
| Full Name | Mrs Margie Castaneda |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 2601 Clark Blvd, Laredo, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033382817 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 200400447322 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Margie Castaneda, RN MSN FNP BC 2601 Clark Blvd, Laredo, TX 78043 Ph: (956) 795-4774 | Mrs Margie Castaneda, RN MSN FNP BC 2601 Clark Blvd, Laredo, TX 78043 Ph: (956) 795-4774 |
News Archive
Stomach MRI images combined with functional fMRI of the brain activity have provided scientists new insight into how the brain listens to the stomach during eating.
Breast cancer is one of the most common forms of cancer and cancer deaths among women worldwide. Routine screening can increase breast cancer survival by detecting the disease early and allowing doctors to address it at this critical stage.
Kamada, Ltd., a biopharmaceutical company engaged in development, production and marketing of specialty life-saving therapeutics and Baxter International Inc., a global, diversified healthcare company announced today that they have entered into an exclusive distribution and manufacturing agreement for Kamada's liquid, ready to use, intravenous Alpha-1 Antitrypsin Product for the treatment of hereditary Alpha-1 Antitrypsin Deficiency approved by the USFDA on July 1st, 2010 for marketing under the trade name "Glassia™".
A landmark study published in the New England Journal of Medicine today heralds a new era in stroke treatment across the globe.
Repros Therapeutics Inc. today announced it has received IRB approval to commence the low dose Proellex® study. The contract for clinical services was previously awarded to ICON. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion. The study will test 5 different doses of Proellex (1, 3, 6, 9 and 12 mg) with 1 mg being the first dose tested. In previous studies a 12.5 mg dose was well tolerated and yielded statistically significant efficacy signals for both uterine fibroids and endometriosis.
› Verified 9 days ago
Delores Vait Rodriguez, FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1801 Gustavus St, Laredo, TX 78043 Phone: 956-724-4574 Fax: 956-523-0120 | |
Raul Rogelio Cortes, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2605 N Arkansas Ave, Laredo, TX 78043 Phone: 956-568-3970 | |
Maria D Villarreal, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1515 Pappas St, Laredo, TX 78041 Phone: 956-523-3683 Fax: 956-718-6294 | |
Erica Gisela Nava, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 7215 Mcpherson Rd, Laredo, TX 78041 Phone: 956-722-8046 | |
Haley Slight Martinez, MSN, APRN, FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1405 Jacaman Rd Ste 104, Laredo, TX 78041 Phone: 956-727-3047 Fax: 956-717-3630 | |
Bianca Blackstone, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1700 E Saunders St, Laredo, TX 78041 Phone: 956-796-5000 |